VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Spigel on CheckMate-331 Trial for SCLC

David Spigel, MD
Published: Wednesday, Jun 29, 2016


David Spigel, MD, chief scientific officer, director, Lung Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the ongoing CheckMate-331 trial, which is investigating nivolumab (Opdivo) versus chemotherapy in relapsed patients with small cell lung cancer (SCLC) after first-line platinum-based chemotherapy.

The open-label, international, randomized phase III trial, which is exploring the role of nivolumab versus topotecan, is currently enrolling patients. The primary endpoint, Spigel adds, is overall survival.

Researchers are hopeful that the immunotherapy agent will show a survival benefit when compared with topotecan, as well as demonstrate a more favorable safety profile.

David Spigel, MD, chief scientific officer, director, Lung Cancer Research Program, principal investigator, Sarah Cannon Research Institute, discusses the ongoing CheckMate-331 trial, which is investigating nivolumab (Opdivo) versus chemotherapy in relapsed patients with small cell lung cancer (SCLC) after first-line platinum-based chemotherapy.

The open-label, international, randomized phase III trial, which is exploring the role of nivolumab versus topotecan, is currently enrolling patients. The primary endpoint, Spigel adds, is overall survival.

Researchers are hopeful that the immunotherapy agent will show a survival benefit when compared with topotecan, as well as demonstrate a more favorable safety profile.



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x